AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway
Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors
High-affinity antibodies against extracellular components of the inflammasome pathway show inhibition of target inflammatory responses
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced recent advancements in its small molecule- and antibody-based therapeutic programs targeting the (NOD)-like receptor protein 3 (NLRP3) inflammasome, a multi-protein complex that activates downstream inflammatory pathways leading to neuronal damage. The inflammasome is a highly valued therapeutic target implicated in a wide range of neurodegenerative disorders including Alzheimer’s disease (AD), as well as in non-central nervous system (CNS) indications, such as autoimmune and infectious diseases, as well as certain cancers.